Skip to main content
20240523 PM  Hoelzel Herrlinger Layer 1212 wp header

News categories: Publication

Novel RNA therapy effective against aggressive brain tumors

Glioblastomas are particularly aggressive brain tumors that quickly invade healthy brain tissue. Since these tumors cannot usually be completely removed surgically, the prognosis for glioblastoma patients is very poor. The standard therapy, which consists of a combination of surgery, radiation, and chemotherapy, does not offer a cure. Therefore, there is an urgent need for effective treatment options. Researchers at the University Medical Center Mannheim (UMM), the DKFZ-Hector Cancer Institute at UMM, and the University Hospital Bonn (UKB) are investigating a new therapy involving a novel class of drugs made from RNA polymers, known as Spiegelmers, which aim to block the regeneration of glioblastomas.

In 2019, the GLORIA study was launched including six university hospitals in Germany under Mannheim leadership. This study is the first to investigate how the drug Olaptesed Pegol (NOX-A12, TME Pharma) works in combination with radiation therapy in glioblastoma patients.

"The unique aspect of our therapeutic approach is that we are no longer focusing solely on the radiation effects in tumor cells but also on their environment, the so-called tumor microenvironment. The Spiegelmer NOX-A12 prevents the formation of new blood vessels through a mechanism that is specifically triggered by remaining tumor cells after radiation therapy to regenerate," explains Professor Dr. Frank Giordano, Director of the Department of Radiation Therapy at UMM, who also conducts research for the DKFZ-Hector Cancer Institute.

Tumor cells depend on the supply of nutrients and oxygen in the blood. They emit signaling molecules that promote the formation of new blood vessels and encourage them to grow towards and nourish the tumor. Even deadly brain tumors attempt to regenerate in this way after therapy. CXCL12 is one such endogenous signaling molecule that stimulates blood vessel formation. The Spiegelmer NOX-A12 inhibits CXCL12 and thus hinders the tumor's regeneration. "Interestingly, the principle seems to work only in combination with radiation therapy because glioblastomas use this repair mechanism via CXCL12 particularly after irradiation," emphasizes Professor Giordano.

In a preliminary Phase I/II study, the new therapy was first tested on a small group of patients with newly diagnosed glioblastomas resistant to standard therapy. The primary aim was to gather information about the safety and preliminary efficacy of NOX-A12 in combination with radiation therapy.

Additionally, the study provided new insights crucial for the further development of the NOX-A12 therapy. Under the leadership of research groups at the University Hospital Bonn, tumor tissue samples were examined using state-of-the-art methods. "When the tumor cells and, interestingly, the vascular cells themselves produce a lot of CXCL12, it seems to correlate with a better response to NOX-A12 therapy," explains Professor Dr. Michael Hölzel, Director of the Institute for Experimental Oncology at UKB, who also conducts research at the University of Bonn. "However, further studies and a larger number of samples are needed to substantiate this observation," Professor Hölzel notes.

The initial data are promising enough that the US Food and Drug Administration (FDA) has not only accepted the application for NOX-A12 as a new investigational drug (IND) but has also endorsed the application for Fast-Track Designation, thereby shortening a process that usually takes several years.

The study involves the university hospitals in Mannheim, Bonn, Essen, Münster, Tübingen, and Leipzig. The results of the study have been published in the renowned journal Nature Communications.

Publication:

Frank A. Giordano, Julian P. Layer, Sonia Leonardelli, et al.

L-RNA aptamer-based CXCL12 inhibition combined 1 with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial

Nature Communications, DOI: 10.1038/s41467-024-48416-9

Contact:

Prof. Dr. med. Michael Hölzel

Director of the institute of Experimental Oncology

University Hospital Bonn

E-Mail: Michael.Hoelzel@ukbonn.de

Press contact:

Jana Schäfer

Deputy Press Officer

University Hospital Bonn, Communication and Media

E-Mail: jana.schaefer2@ukbonn.de

Related news

News Florian Schmidt 09 2024

News categories: Publication

Central mechanism of inflammation decoded

The formation of pores by a particular protein, gasdermin D, plays a key role in inflammatory reactions. During its activation, an inhibitory part is split off. More than 30 of the remaining protein fragments then combine to form large pores in the cell membrane, which allow the release of inflammatory messengers. As methods for studying these processes in living cells have so far been inadequate, the sequence of oligomerization, pore formation and membrane incorporation has remained unclear until now.
View entry
Larvae of the fruit fly Drosophila (foreground) - have a kind of stretch sensor in the esophagus (grey structure in the middle). It reports swallowing processes to the brain. If food is ingested, special neurons of the enteric nervous system (red) release serotonin.

News categories: Publication

Swallowing triggers a feeling of elation

Researchers at the University of Bonn and the University of Cambridge have identified an important control circuit involved in the eating process. The study has revealed that fly larvae have special sensors, or receptors, in their esophagus that are triggered as soon as the animal swallows something. If the larva has swallowed food, they tell the brain to release serotonin. This messenger substance ensures that the larva continues to eat. The researchers assume that humans also have a very similar control circuit. The results were recently published in the journal “Current Biology.”
View entry
Sophie Binder, Gregor Hagelüken, Niels Schneberger in the laboratory

News categories: Publication

Gene scissors switch off with built-in timer

CRISPR gene scissors, as new tools of molecular biology, have their origin in an ancient bacterial immune system. But once a virus attack has been successfully overcome, the cell has to recover. Researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with researchers from the Institut Pasteur in France, have discovered a timer integrated into the gene scissors that enables the gene scissors to switch themselves off. The results of the study have been published in the renowned journal "Nucleic Acids Research".
View entry

Back to the news overview